+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
ID07318129

Study of Indole-3-propionic Acid Supplementation as a Treatment for Relapsing-Remitting Multiple Sclerosis

Led by Glostrup University Hospital, Copenhagen · Updated on 2026-01-28

220

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of oral supplementation with indole-3-propionic acid IPA, a natural gut bacterial metabolite, in patients with relapsing-remitting multiple sclerosis RRMS. The main goal is to see if IPA can help protect against MS-related disease activity, nerve damage, and metabolic problems. The study also aims to understand how lifestyle, gut bacteria, inflammation, oxidative stress, and metabolic health relate to MS severity and activity. Participants will be randomly assigned to receive either IPA capsules or placebo capsules. They will take two capsules every morning and evening for 27 months. The IPA capsules contain 250 mg each, totaling 1000 mg daily. The study is quadruple-blinded, meaning participants and researchers do not know who receives IPA or placebo during the trial. During the study, participants will have regular assessments including brain MRIs, blood and fecal sample collections, and various neurological and cognitive tests. Researchers will monitor disease activity, relapse rates, brain lesions, disability, metabolic markers, inflammation, and quality of life over the 27 months. The main outcome is measuring no evidence of disease activity NEDA between months 3 and 27 after starting supplementation.

CONDITIONS

Brief Title

Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis

Research Team

J

Jette Lautrup Frederiksen, MD, dr.med, professor

M

Moschoula Passali, MSc, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here